August 2016, Vol. 5, No. 6
Phase 3 Evidence for New Standard in Elderly Glioblastoma Patients
Short-course (hypofractionated) radiotherapy (RT) and temozolomide (TMZ) followed by TMZ significantly prolonged survival versus short-course RT alone in newly diagnosed elderly patients with glioblastoma. These results of a global cooperative group phase 3 trial were 1 of 4 talks selected for the plenary session at the 2016 ASCO Annual Meeting.
âAlthough glioblastoma disproportionately affects older patients, there are no clear guidelines for treating these patients, and practice varies globally,â said lead author James Perry, MD, The Crolla Family Endowed Chair in Brain Tumour Research at the Odette Cancer and Sunnybrook Health Sciences Center, Toronto, Canada.
âThis is the first evidence from a randomized clinical trial that chemotherapy in combination with a shorter radiation schedule significantly extends survival without a detriment to quality of life,â Dr Perry told listeners.
The accepted standard treatment of glioblastoma is surgical resection and 6 weeks of RT plus chemotherapy with TMZ, but this is based on evidence from a pivotal trial that did not include elderly patients.
The only studies conducted in the elderly compared different RT schedules head to head and RT alone versus TMZ monotherapy, he explained.
âTherefore, the only evidence-based choices for elderly patients with newly diagnosed glioblastoma are RT alone or TMZ alone,â he emphasized.
The phase 3 study randomized 562 newly diagnosed patients with glioblastoma (age >65 years) in a 1:1 ratio to short-course RT (40 Gy/15 fractions/3 weeks) plus concomitant TMZ for 3 weeks and monthly adjuvant TMZ (12 treatment cycles) versus short-course RT alone.
In an intent-to-treat analysis, overall survival (OS) was improved from 7.6 months with RT alone to 9.3 months with RT plus TMZ (P <.0001). Progression-free survival (PFS) was also improved by RT plus TMZ. Median PFS was 5.3 months for the combination versus 3.9 months for RT alone (P <.0001).
The 1-year and 2-year survival rates were 37.8% and 10.4% with the combination of RT plus TMZ versus 22.2% and 2.8%, respectively, for RT alone.
âAlthough the difference in median survival seems modest, temozolomide significantly increased the chances of surviving 2 or 3 years. For an individual patient, that can mean being able to be part of another family holiday or celebration,â Dr Perry said.
MGMT methylation analysisâa marker of responseâwas assessed in tissue from 462 patients. Patients whose tumors showed MGMT methylation had the most robust improvement in OS: in patients with methylated tumors, median OS was 13.5 months for the combination of RT and TMZ versus 7.7 months with RT alone (P = .0001).
In patients with unmethylated tumors, OS was 10 months for the combination versus 7.9 months for RT alone, for a 25% improvement.
âTo our surprise, patients with unmethylated tumors also got benefit from the combination versus RT alone,â Dr Perry told listeners.
Side effects for RT plus TMZ were minimal: mainly transient increases in nausea and vomiting during the first week and slight increases in grades 3 and 4 hematologic toxicities in less than 5% of patients.
âShorter-course RT plus TMZ significantly improves survival compared to RT alone in newly diagnosed elderly patients with glioblastoma. The benefit was observed mostly in patients with MGMT promoter methylation, but clinical benefit was also seen in patients with unmethylated tumors, with no sacrifice in quality of life and with manageable toxicities. Oncologists now have evidence to consider RT with TMZ in all newly diagnosed elderly patients with glioblastoma,â Dr Perry stated.
At the plenary session, Deborah Schrag, MD, MPH, of the Dana-Farber Cancer Institute, Boston, MA, said that TMZ was of âmoderate valueâ in elderly patients with glioblastoma based on the ASCO and ESMO value frameworks.
Further, in the absence of a specific mutation (MGMT promoter methylation), she rated TMZ as âlow value.â
She noted that the availability of generic temozolomide makes it more likely that the drug will be used.
Refining Use of CAR-T in ALL
Chimeric antigen receptor T-cells (CAR-T) have saved lives in some patients with acute lymphoblastic leukemia (ALL) who had run out of other treatment options. This type of immunotherapy is making inroads in other hematologic malignancies as well, but it is still being studied in very sick patients.The downside of CAR-T [ Read More ]
Addition of Bcl-2 Inhibitor to MM Regimen Produces Promising Responses in Relapsed/Refractory MM
Venetoclax, an investigational oral selective small molecule Bcl-2 inhibitor, added to bortezomib and dexamethasone resulted in impressive response rates in a phase 1b trial of patients with heavily pretreated relapsed/refractory (RR) multiple myeloma (MM). In the trial, the objective response rate (ORR) was higher among patients whose myeloma cells produced [ Read More ]